Cargando…
Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors, such as evolocumab, are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with primary hypercholesterolemia or mixed dyslipidemia. OBJECTIVE: This study assessed the cost effectiveness of evolocum...
Autores principales: | Alghamdi, Ahmed, Balkhi, Bander, Altowaijri, Abdulaziz, Al-shehri, Nasser, Ralph, Lewis, Marriott, Emily-Ruth, Urbich, Michael, Aljanad, Fawaz, Aziziyeh, Rima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864041/ https://www.ncbi.nlm.nih.gov/pubmed/34582002 http://dx.doi.org/10.1007/s41669-021-00300-8 |
Ejemplares similares
-
Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study
por: Alghamdi, Ahmed, et al.
Publicado: (2021) -
Pharmacy students attitude and perception toward working in community pharmacy in Saudi Arabia
por: Balkhi, Bander, et al.
Publicado: (2020) -
The burden of bites and stings management: Experience of an academic hospital in the Kingdom of Saudi Arabia
por: Khan, Anas, et al.
Publicado: (2020) -
The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021) -
Survival and Estimation of Direct Medical Costs of Hospitalized COVID-19 Patients in the Kingdom of Saudi Arabia (Short Title: COVID-19 Survival and Cost in Saudi Arabia)
por: Khan, Anas A., et al.
Publicado: (2020)